Evercore ISI Group Maintains Outperform on Avidity Biosciences, Lowers Price Target to $53
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group has maintained an 'Outperform' rating on Avidity Biosciences but has slightly lowered the price target from $54 to $53.
August 26, 2024 | 1:14 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Evercore ISI Group has maintained an 'Outperform' rating on Avidity Biosciences, indicating continued confidence in the company's performance. However, the price target has been slightly reduced from $54 to $53, suggesting a minor adjustment in expected valuation.
The 'Outperform' rating suggests that the analyst expects the stock to perform better than the market average. The slight reduction in the price target indicates a minor adjustment in expectations, but overall confidence in the stock remains high.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100